Table 3A) Primary End Points
Primary End Points All (n = 403) RF (n = 345) Cryo (n = 58) p value
AAR 179 (44.4) 151 (43.8) 28 (48.3) p = 0.52
Antiarrhythmic use 55 (13.6) 45 (13.0) 10 (17.2) p = 0.51
Repeat ablation 73 (18.1) 65 (18.8) 8 (13.8) p = 0.46
Cardioversion 75 (18.6) 63 (18.3) 12 (20.7) p = 0.80
Table 3B)
AAR by Utah Stage
Utah Stage 1+2 All (n = 232) RF (n = 200) Cryo (n = 32) p value
AAR 103 (44.4) 88 (44.0) 15 (46.9) p = 0.91
Utah Stage 3+4 All (n = 171) RF (n = 145) Cryo (n = 26) p value
AAR 76 (44.4) 63 (43.4) 13 (50.0) p = 0.69